Biogen Inc

NASDAQ: BIIB
$199.36
-$2.08 (-1.0%)
Closing Price on September 20, 2024

BIIB Articles

Biogen Idec shares rallied on news that its MS drug has posted positive trial results. F5 reported a strong quarter as did Intel. S&P 500 WEEK TOP 10 (15 APR – 21 APR) Ticker Weekly Price...
These are the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Tuesday morning. Abercrombie & Fitch Co. (NYSE: ANF) Started as Overweight at Barclays;...
Biotech is becoming the ever-shrinking stock sector.  It is almost weekly now that a new biotech acquisition is announced.  Big Pharma in the United States and large drugmakers internationally...
We have many stocks on the move this morning.  Our top pre-market movers for active traders and day traders alike are Apollo Group Inc. (NASDAQ: APOL), Barclays PLC (NYSE: BCS), Royal Bank of...
The research calls are running light as many markets either close early or are on very low volume with skeleton crews manning the trading desks.  These are some of this Friday’s key analyst...
These are some of this Tuesday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Started as Neutral at Credit Suisse. AstraZeneca...
Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally.  It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, and a successful...
Active traders and day traders have several key stocks to watch.  We are tracking moves in Adobe Systems, Inc. (NASDAQ: ADBE), Biogen Idec Inc. (NASDAQ: BIIB), Deutsche Bank AG (NYSE: DB), Microsoft...
Biotech and BioHealth stocks are on the move today and there is more news in the emerging sector than there has been on a single day in months and months.  The news is not even on any of the...
These are some of this Thursday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls: Amgen Inc. (NASDAQ: AMGN) Started as Buy at Stifel Nicolaus. AngloGold...
All of the freshest reports have the Genzyme Corporation (NASDAQ: GENZ) buyout discussions between Sanofi-Aventis (NYSE: SNY) as being a friendly merger.  The first discussions noted by the WSJ were...
Genzyme Corporation (NASDAQ: GENZ) is flying high on reports that Sanofi-Aventis (NYSE: SNY) may have an interest in buying the company.  The WSJ reports that the large drug giant has approached...
Sanofi-Aventis SA (NYSE: SNY) was a bit of a stalking horse news item on a week that many investors and traders started taking off for a long weekend.  The company has tried to telegraph the...
Biotech is the land of promise for emerging players.  It is also the land of stagnation for well established and sturdy giants.  Amgen, Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), and...
Today’s version of the BioHealth Business Daily is again full of stocks on the move with news, and some not on news.  Array BioPharma, Inc. (NASDAQ: ARRY), BioDelivery Services International Inc....